#USA #Chicago #Taiho Oncology #Zipalertinib #ASCO 2025

Taiho Oncology Showcases Innovative Treatments at ASCO 2025

Taiho Oncology, Inc. has made a significant announcement regarding its participation in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 at McCormick Place in Chicago. This year, the company is set to present promising new data through two oral presentations, a poster display, and two online abstracts. The highlights include a potential novel, all-oral treatment regimen for acute myeloid leukemia (AML) and important Phase 2 data for a new therapy targeting non-small cell lung cancer (NSCLC) with specific genetic mutations.

Key Presentations and Findings

The first oral presentation will focus on an innovative combination of decitabine and cedazuridine with venetoclax, proposed as an all-oral regimen for patients newly diagnosed with AML who are not candidates for standard intensive chemotherapy. According to the Chief Medical Officer of Taiho Oncology, Dr. Harold Keer, this treatment approach aligns with the company's mission to enhance the lives of cancer patients and minimize the burden on their families and caregivers by offering greater flexibility in treatment options.

In this Phase 1/2 clinical trial involving 101 patients, the combination therapy achieved complete remission (CR) rates of approximately 46.5%, with a notably rapid median time to first CR at just 2.4 months. Impressively, 80% of patients maintaining CR status at the 6-month mark indicates the potential effectiveness of this all-oral regimen. Adverse events were reported to be mostly grade 3 or lower, with manageable side effects.

The second oral presentation will delve into the investigational drug zipalertinib, which targets NSCLC patients with EGFR exon 20 insertion mutations. Positive safety and efficacy data from the Phase 2b REZILIENT study show that zipalertinib achieved an overall response rate (cORR) of 35.2% among the treatment population. This finding is particularly relevant given that many of the patients had a history of previous therapies and brain metastases.

Taiho Oncology is also set to present data derived from real-world studies evaluating the performance of two existing FDA-approved therapies. As stated by President and CEO Tim Whitten, the company is committed to making a substantial impact in the oncology field, emphasizing that these presentations at ASCO underline their dedication to meaningful innovation across multiple types of cancer.

Additional Presentations

Notably, Taiho Oncology will feature a poster presentation on treatment patterns in metastatic colorectal cancer involving trifluridine/tipiracil, in combination with bevacizumab. Attendees can engage with this research during the poster session scheduled for May 31. Furthermore, online abstracts will provide insights into patient characteristics and outcomes, contributing to the overall understanding of treatment effectiveness in various cancer scenarios.

Taiho Oncology is on a mission to improve cancer care through developing and commercializing new therapies, including orally administered anti-cancer agents targeting various malignancies. The organization's perseverance and dedication toward the research and development of innovative treatments align strongly with the growing need for effective options in the oncology landscape. As they continue to evolve, the data presented at ASCO 2025 is expected to be a pivotal moment in Taiho's ongoing journey in the fight against cancer.

Conclusion

The upcoming ASCO 2025 presents a valuable platform for Taiho Oncology to share crucial data that may shape future treatment paradigms in oncology. By showcasing new advancements and treatment options, the company is carving a path toward better outcomes for cancer patients worldwide. The emphasis on all-oral treatment regimens and targeted therapies highlights a promising future in personalized cancer care, as Taiho Oncology remains steadfast in its commitment to innovation and patient-centered solutions.